- Kenvue becomes a fully independent company following final separation . . .
SKILLMAN, N J August 23, 2023 – Kenvue Inc (NYSE: KVUE) (“Kenvue”) today announced its separation from Johnson Johnson, marking its first day as a fully independent company
- Johnson Johnson Announces Final Results of Exchange Offer and . . .
NEW BRUNSWICK, N J , August 23, 2023 – Johnson Johnson (NYSE: JNJ) today announced the final results of its previously announced offer to its shareholders to exchange their shares of Johnson Johnson common stock for shares of Kenvue Inc (NYSE: KVUE) (“Kenvue”) common stock owned by Johnson Johnson
- Johnson Johnson Spins Off Kenvue in Biggest IPO Haul Since 2021
Johnson Johnson (JNJ) spun off its Kenvue (KVUE) consumer brands division on Thursday, raising the most cash from an initial public offering (IPO) in more than a year
- Johnson Johnson Offers Exchange for Shares of Spinoff Kenvue
Johnson Johnson (JNJ) will spin off at least 80 1% of its shares in consumer health company Kenvue (KVUE) through an exchange offer, the company said Monday J J shareholders will have the
- Johnson Johnson to keep a 9. 5% stake in consumer health spinoff . . .
After Johnson Johnson initiated a share-exchange offer to significantly reduce its holdings in Kenvue, the company says it's keeping about a 9 5% stake in the consumer health spinoff
- Kenvue IPO: Everything you need to know about the JNJ spin off
Healthcare giant Johnson Johnson (JNJ) is expected to spin off its consumer arm, most known for its plasters, baby shampoo and Listerine brand of mouthwash This move marks the largest restructuring in the company’s 135-year history
- Does Johnson Johnsons Kenvue Spinoff Make Sense?
Johnson Johnson is spinning off Kenvue, the consumer health stable, which includes brands like Band-Aid, Tylenol, and Neutrogena
- Johnson Johnson initiates spin-off and IPO of Kenvue division . . .
With this placement, which will happen within a few weeks, J J plans to sell more than 151 million Kenvue shares at a price of between $20 and $23 per share, raising a maximum of $3 5 billion After the deal, and assuming the oversubscription right is exercised, J J will retain 90 8% of the consumer subsidiary
|